Iridex CORP 10-Q quarterly reports

IRIDEX Corporation's Q1 2026 results show a marginal decrease in total revenues to $11.8 million, with a net loss of $0.5 million, impacted by a decline in retina product sales.

IRIDEX Corporation announced increased revenues and a narrower operating loss for the third quarter and first nine months of fiscal year 2025, driven by product sales and cost-saving measures.

IRIDEX Corporation reported a significant reduction in net loss and improved cash position for the six months ended June 28, 2025, driven by cost savings and new capital raises, despite a slight decline in gross margin.

IRIDEX Corporation's Q1 2025 results show a slight revenue increase and a significant reduction in operating expenses, alongside a $6 million investment through Series B Preferred Stock.

Iridex Corp's Q3 2024 results show a revenue decrease of 9.9% compared to the same period last year, impacted by softer demand and lower royalties.

IRIDEX Corporation's Q2 2024 results show a decrease in revenue and a net loss, but the company is implementing cost-saving measures and has secured new financing to address liquidity concerns.

IRIDEX Corp's Q1 2024 results show a decrease in revenue and gross profit, alongside concerns about the company's ability to continue as a going concern.